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Elevated levels of circulating low-density lipoprotein cholesterol (LDL-C) play a central role in the development of
atherosclerosis. Mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9) that are associated with lower plasma
levels of LDL-C confer protection from coronary heart disease. Here, we show that four severe loss-of-functionmutations
prevent the secretion of PCSK9 by disrupting synthesis or trafﬁcking of the protein. In contrast to recombinant wild-
type PCSK9, which was secreted from cells into the medium within 2 hours, the severe loss-of-function mutations in
PCSK9 largely abolished PCSK9 secretion. This ﬁnding predicted that circulating levels of PCSK9 would be lower in
individuals with the loss-of-functionmutations. Immunoprecipitation and immunoblotting of plasma for PCSK9provided
direct evidence that the serine protease is present in the circulation and identiﬁed the ﬁrst known individual who has
no immunodetectable circulating PCSK9. This healthy, fertile college graduate, who was a compound heterozygote for
two inactivating mutations in PCSK9, had a strikingly low plasma level of LDL-C (14 mg/dL). The very low plasma level
of LDL-C and apparent good health of this individual demonstrate that PCSK9 plays a major role in determining plasma
levels of LDL-C and provides an attractive target for LDL-lowering therapy.
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In 2003, Abifadel and colleagues1 reported that selected
missense mutations in PCSK9 (proprotein convertase sub-
tilisin/kexin type 9 [MIM 607786]), which encodes a cho-
lesterol-regulated proprotein convertase,2,3 cause a new
form of autosomal dominant hypercholesterolemia (MIM
603776). This discovery revealed a previously unrecog-
nizedmechanism that strongly inﬂuences the level of low-
density lipoprotein cholesterol (LDL-C) in the circulation.
PCSK9 comprises a signal sequence, a prodomain, a cat-
alytic domain, and a cysteine-rich C-terminal domain (ﬁg.
1A).7 Like other proprotein convertases, PCSK9 undergoes
autocatalytic cleavage in the endoplasmic reticulum (ER)
at residue 152, between the prodomain and the catalytic
domain.8 The prodomain and the catalytic domain remain
tightly associated and are secreted together from cultured
cells.7,9 High-level expression of wild-type PCSK9 (PCSK9-
WT) in the liver of mice results in a pronounced reduction
in hepatic low-density lipoprotein receptor (LDLR)protein
(but not mRNA).10,11 Since hepatic LDLR-mediated endo-
cytosis is the major route of LDL clearance,12 the mice
expressing high levels of PCSK9 in the liver are severely
hypercholesterolemic. In contrast, mice expressing no
PCSK9 have accelerated LDL clearance.13 These ﬁndings
indicate that PCSK9 acts to limit the number of LDLRs at
the cell surface. Thus, the PCSK9 mutations associated
with hypercholesterolemia are presumably gain-of-func-
tion mutations.
Whereas gain-of-function mutations in PCSK9 in hu-
mans are apparently rare, a spectrum of more-frequent
loss-of-function mutations associated with low LDL-C lev-
els have been identiﬁed.4–6 Elsewhere, we demonstrated
that 2%–2.6% of African Americans are heterozygous for
one of two nonsense mutations in PCSK9 (Y142X and
C679X).4,14 These mutations are associated with a 30%–
40% reduction in plasma levels of LDL-C and an 88%
reduction in coronary heart disease over a 15-year peri-
od.4,14 Other amino acid substitutions in PCSK9 repro-
ducibly associated with signiﬁcant reductions in plasma
levels of LDL-C include R46L, L253F, and A443T; individ-
uals heterozygous for these sequence variations have a
15%, 30%, and 2% reduction in plasma levels of LDL-C,
respectively5,6 (ﬁg. 1A). The effects of PCSK9 mutations on
plasma levels of LDL-C and coronary heart disease suggest
that PCSK9 is amajor determinant of plasma levels of LDL-
C and may be an attractive target for cholesterol-lowering
therapy. However, the mechanism(s) by which these mu-
tations affect PCSK9 function has not been fully deﬁned.
High-level expression of PCSK9 in cultured hepatocytes
resulted in degradation of the LDLR in a post-ER com-
partment,15 but evidence supporting an extracellular ef-
fect of PCSK9 on LDLR number has also been reported.16
Furthermore, the phenotypic effects of total deﬁciency of
PCSK9 have not been determined: to date, only hetero-
zygotes for the severe loss-of-function mutations have
been described. Here, we examined the effect of loss-of-
function mutations on the synthesis and secretion of
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Figure 1. Effects of loss-of-function mutations on the synthesis
and secretion of PCSK9. A, PCSK9, a protein of 692 aa that contains
a signal sequence (SS), a 122-aa prodomain (Pro), a catalytic
domain, and a C-terminal domain. The locations of the catalytic
triad (D186, H226, and S386), oxyanion hole residue (N317), site
of attachment of the N-linked sugar (533), and loss-of-function
mutations4–6 are shown. B, Expression of recombinant PCSK9 in
HEK-293 cells. Wild-type (WT) and mutant forms of PCSK9 were
expressed in HEK-293 cells, and immunoblotting was performed
on the cells and medium with use of an anti-FLAG M2 mAb, as
described in the “Material and Methods” section. This experiment
was repeated three times, with similar results. Lane C p control;
P p precursor; M p mature; S p secreted.
PCSK9.We found that the threemutations associatedwith
the greatest reductions in plasma levels of LDL-C inter-
fered with either the synthesis or the secretion of PCSK9.
On the basis of these ﬁndings, we predicted that PCSK9
circulates in plasma and that individuals with two inac-
tivating mutations in PCSK9 would have no circulating
PCSK9. Immunoprecipitation and immunoblotting of plas-
ma from family members of probands with PCSK9 mu-
tations conﬁrmed that the serine protease is present in the
circulation and identiﬁed the ﬁrst known individual with
no immunodetectable circulating PCSK9.
Material and Methods
Material
Rabbit polyclonal antibodies against full-length recombinant hu-
man PCSK9 (6389) and the catalytic domain of human PCSK9
(295A) were generated and puriﬁed. A polyclonal antibody IgG
puriﬁed from serum of a nonimmune rabbit was provided by
Russell DeBose-Boyd (UT Southwestern). Monoclonal antibody
(15A6) was generated by fusion of Sp2/mIL-6 (ATCC catalognum-
ber CRL-2016) mouse myeloma cells with splenic B-lymphocytes
derived from a female BALB/c mouse that was injected with full-
length human PCSK9 protein by use of techniques described else-
where.17 The antibody belongs to the IgG subclass 1 and recog-
nizes epitopes in the C-terminal region of PCSK9. Mouse anti-
FLAGM2monoclonal antibody was purchased from Sigma. Unless
otherwise speciﬁed, all other reagents were obtained from Sigma.
Expression Constructs for PCSK9-WT and Mutant Forms
of PCSK9
An expression vector encoding amino acids 1–692 of human
PCSK9 followed by a FLAG epitope tag (DYKDDDDK) under the
control of the cytomegalovirus promoter-enhancer (pCMV-PCSK9-
FLAG) was constructed in pcDNA3.1. Constructs expressing the
truncation mutations (Y142X and C679X) were generated using
the following primers: 5′ primer (5′-GCTCTAGAATGGGCACCGT-
CAGCTCCAG-3′) and 3′ primer (5′-GCGAAGCTTCTAGTCGACA-
TGGGGCAACT-3′) for Y142X and 3′ primer (5′-GCGAAGCTTTCA-
GCAGATGGCAACGGCTG-3′) for C679X. The 5′ and 3′ primers
contained XbaI and HindIII restriction sites, respectively. The
PCR-ampliﬁed cDNA was then digested with XbaI and HindIII
before ligation into pACCMVpLpA(1)loxP-SSP (provided by Rob-
ert Gerard [UT Southwestern]).
Single base-pair changes were introduced into the human PCSK9
cDNA expression constructs by use of QuikChange (Stratagene)
as described elsewhere.18 Sequences of the oligonucleotides used
to generate the expression constructs are available on request.
The presence of the desired mutation and the ﬁdelity of each
construct were conﬁrmed by DNA sequencing.
Transfections and Cell Lysates
Human embryonic kidney (HEK)–293 cells were seeded ( 51 # 10
cells/well) in 6-well plates. Expression plasmids (1 mg/well) were
transiently transfected into HEK-293 cells with Fugene (6 ml of
Fugene/mg of DNA) according to the manufacturer’s protocol
(Roche Diagnostics). After a 48-h transfection, the medium was
replaced with supplemental medium (Dulbecco’s modiﬁed Eagle
medium with 1% insulin-transferrin-selenium [Cellgro; Media-
tech]). After 5 h, the medium was collected, and the protein was
precipitated with trichloroacetic acid. Cells were washed twice in
PBS (pH 7.4), were incubated in 0.2 ml of Triton lysis buffer (50
mM Tris, 80 mM NaCl, 2 mM CaCl2, 1% [v/v] Triton X-100, and
complete mini EDTA-free protease inhibitor cocktail [Roche]) for
30 min at 4C, and were harvested by scraping with a rubber
policeman. Cells and lysis buffer were transferred to 1.5-ml tubes
and were centrifuged for 15 min ( at 4C). Supernatants15,000 g
were subjected to SDS-PAGE and immunoblot analysis.
Analysis of Glycosylation
Cell lysates and medium were collected from HEK-293 cells 48 h
after transfection with PCSK9-expression constructs. The lysates
and medium were denatured by heating (at 95C for 10 min) in
0.5% SDS and 1 mM b-mercaptoethanol (b-ME) and were incu-
bated overnight in the presence or absence of 10 units of pep-
tide—N-glycosidase F (PNGaseF) or Endo H (New England Bio-
labs)—according to the manufacturer’s protocol. Samples were
then diluted with sample loading buffer, were heated to 95C for
5 min, were subjected to SDS-PAGE at 20 V for 20 h, and were
immunoblotted using an anti-FLAG M2 monoclonal antibody
(mAb).
SDS-PAGE and Immunoblot Analysis of PCSK9
Protein concentrations were determined using the Bio-Rad bicin-
choninic acid assay, according to the manufacturer’s protocol.
Sample loading buffer was added to a ﬁnal concentration of 1#,
and samples were heated to 95C for 5 min. Proteins were size-
fractionated on 8% or 10% SDS-polyacrylamide gels at 100 V and
were subsequently transferred to nitrocellulosemembranes at 100
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Figure 2. Pulse-chase analysis of the synthesis, processing, and
secretion of PCSK9-253F and PCSK9-679X. A, Cells expressing PCSK9-
WT (WT) or mutant PCSK9 were incubated with 0.1 mCi/ml S35-
Cys/Met for 10 min and then were chased for the indicated time
periods. PCSK9 was immunoprecipitated from cell lysates and me-
dium with use of antibody 6389 and then was subjected to 8%
SDS-PAGE. Proteins were visualized by exposure to XOMAT ﬁlm. B,
PCSK9-WT (WT) and mutant forms of PCSK9 were expressed in HEK-
293 cells, and immunoblotting was performed on the cells and
medium as described in the ﬁgure 1 legend. P p precursor; Mp
mature.
V for 1 h. Membranes were incubated in PBST buffer (1# PBS
[pH 7.4] and 0.5% Tween 20) with 5% dry milk for 60 min at
room temperature (RT) before addition of the primary antibodies.
Primary antibodies were diluted in PBST buffer with 5% dry milk
and were incubated with membranes for 60 min. Membranes
were washed three times for 5 min in PBST buffer. Horseradish
peroxidase–conjugated donkey anti-rabbit IgGor goat anti-mouse
IgG (Pierce) was diluted (1:10,000) in PBST buffer with 5% dry
milk and was incubated with membranes for 60 min. Membranes
were washed three times for 5 min in PBST and were visualized
using SuperSignal-enhanced chemiluminescence (Pierce). Protein
loading was assessed by visual inspection of Ponceau S-stained
membranes.
For the dithiothreitol (DTT) treatment, recombinant PCSK9-
WT and PCSK9-679X were expressed in HEK-293 cells after trans-
fection with Lipofectamine 2000 (Invitrogen) by use of the pro-
tocol provided by the manufacturer. After 48 h at 37C, the cells
were collected in PBS and were isolated by centrifugation (1,000
for 15 min). A total of 100 ml of buffer (50 mM Tris [pH 6.4], 2g
mM CaCl2, and 150 mM NaCl) was added to the cell pellet. The
cells were mechanically disrupted by 30 passages through a 23-
gauge needle. A total of 7.3 mg of cellular protein was incubated
with 4 ml of b-ME–free sample buffer (100 mM Tris [pH 6.5], 2%
SDS, 1 mM EDTA, 20% glycerol, 0.001% bromophenol blue, and
0.05–20 mM DTT) at RT for 1 h. Immunoblotting was performed
as described above, except that the proteins were electroblotted
onto PVDF membrane (Amersham Biosciences).
Pulse-Chase Analysis of PCSK9 Processing and Secretion
Wild-type PCSK9-253F and PCSK9-679X were expressed in HEK-
293 cells with use of Fugene 6 transfection reagent. After 2 d in
culture, the cells were washed twice with cold PBS and were then
incubated with Cys/Met-free medium for 1 h at 37C. Cells were
pulsed with 0.1 mCi/ml S35-Cys/Met for 10 min at 37C and then
were chased for the time intervals indicated in ﬁgure 2. PCSK9
was immunoprecipitated from cell lysates and medium with use
of the polyclonal antibody 6389, and the precipitates were sub-
jected to 8% SDS-PAGE and were visualized by exposure to Biomax
MS ﬁlm.
Immunoprecipitation of PCSK9 from Plasma
After written consent to participate in the institutional review
board–approved study was obtained, fasting blood was collected
from a Dallas Heart Study participant identiﬁed elsewhere to be
heterozygous for the Y142X mutation and from selected family
members.4,19 Plasma was isolated from the blood as described else-
where19 and was aliquoted and maintained at 80C. A total of
500 ml of plasma was adjusted to a ﬁnal concentration of 50 mM
HEPES [pH 7.4], 2.5 mM MgCl2, 1% Triton X-100, 0.5% sodium
deoxycholate, 1 mM phenylmethylsulphonylﬂuoride, and pro-
tease inhibitor cocktail (Roche) in a ﬁnal volume of 1ml. Samples
were rotated at 4C for 30 min and then were centrifuged at
for 15 min. Supernatants were then divided into two21,000 g
500-ml aliquots, and 20 mg of rabbit anti-human PCSK9 antibody
(295A) or 20 mg of puriﬁed IgG from a nonimmunized rabbit
(4752) was added to each aliquot. A total of 50 ml of PBS-equili-
brated protein A agarose beads (RepliGEN) was added to each
sample. The samples were rotated at 4C overnight before being
washed four times with 1# IP buffer (50 mM Hepes [pH 7.4], 100
mM NaCl, 1.5 mM MgCl2, 1% Triton X-100, and 0.5% sodium
deoxycholate). The beads were resuspended in 100 ml SDS-PAGE
sample buffer, were boiled at 96C for 5min, andwere centrifuged
at for 5 min. A total of 30 ml of supernatant was subjected21,000 g
to SDS-PAGE (8%), and immunoblotting was performed using a
monoclonal antibody to PCSK9 (15A6).
Structural Model of PCSK9
A BLAST search20 with use of the PCSK9 sequence giF31317307
identiﬁed the fervidolysin sequence giF56553650 (residue range
25–446, E ) and established an initial alignment of9valuep 10
the two sequences. The sequence of PCSK9 was aligned with the
N-terminal and catalytic domains of the fervidolysin structure
(PDB ID 1r6v) with use of the fold-recognition program Meta-
BASIC,21 which incorporates evolutionary informationandsecon-
dary structure predictions (signiﬁcant score 144.9). The resulting
PCSK9 model structure was generated on the basis of the 1r6v
coordinates with the program MolScript.22 The alignment pro-
duced by PSI-BLAST and the alignment produced by Meta-BASIC
differ in some loop regions and in the extreme N-terminus (res-
idues 1–67 of PCSK9) and C-terminus (residue 420 to the end of
PCSK9); for mutations falling within these regions (R46L, F216L,
and A443T), the range bounded by the BLAST alignment position
and theBASIC alignment positionwere estimated.Alignmentswere
in agreement for the other mutations in the prodomain (DR97 and
S127R) and in the catalytic domain (L253F and D374Y).
Results
Expression of Loss-of-Function Mutations in HEK-293 Cells
PCSK9 is synthesized as an ∼72-kDa soluble zymogen (pre-
cursor) and undergoes autocatalytic cleavage to form an
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Figure 3. Effect of the C679X mutation on the maturation of N-
linked sugars in PCSK9. Cell lysate and medium were collected from
HEK-293 cells expressing PCSK9-WT (WT) and mutant PCSK9 and
were treated with PNGaseF or EndoH as described in the “Material
and Methods” section. Analysis of recombinant PCSK9 containing
an alanine rather than asparagine at the site of attachment of the
N-linked sugar was also performed. Deglycosylated samples were
subjected to 10% SDS-PAGE, and immunoblotting was performed
using anti-FLAG M2 mAb. Pp precursor; Mpmature; Sp secreted.
∼16-kDa prodomain and an ∼62-kDa catalytic and C-ter-
minal domain (mature protein).7,9 To determine the effect
of loss-of-function mutations on PCSK9 synthesis, pro-
cessing, and secretion, we expressed recombinant forms
of the protein in HEK-293 cells and analyzed the cell lys-
ates and medium for the presence of PCSK9 (ﬁg. 1B). The
twomutations associated withmore-modest reductions in
plasma LDL-C levels (R46L and A443T) had no detectable
effect on the processing or secretion of PCSK9 (ﬁg. 1B).
The Y142X mutation occurs early in the transcript and is
predicted to initiate nonsense-mediated mRNA decay24;
expression of a cDNA construct containing this mutation
resulted in no immunodetectable protein with use of ei-
ther an antibody to the prodomain or the epitope tag (data
not shown).
In cells expressing PCSK9-253F, the amount of mature
protein was reduced compared with that in cells express-
ing PCSK9-WT, which suggests that the mutation inhibits
autocatalytic cleavage. In contrast to the L253F substitu-
tion, the C679X mutation did not interfere with protein
cleavage. Rather, the mature protein accumulated in the
cells, and none was detected in the medium. Thus, both
the L253F and the C679X mutations interfere with the
secretion of PCSK9.
Interference by PCSK9 Loss-of-Function Mutations
with Protein Processing and Secretion
The effects of the L253F and C679X mutations on PCSK9
processing were conﬁrmed by pulse-chase studies (ﬁg. 2A).
No differences in the synthesis or secretion of the A443T
or the R46L mutations were seen (data not shown). Nei-
ther mutation affected the amount of precursor protein
observed at the 15-min time point. In cells expressing
PCSK9-WT, the precursor protein was fully converted to
the mature form of the protein and was secreted within
2 h. Only a small amount of mature wild-type protein was
detected in cells at any time point, which suggests that
the protein was rapidly secreted after processing. In cells
expressing PCSK9-253F, the precursor was almost com-
pletely retained at the 2-h time point, and only a small
quantity of mature protein was detected in the cells or in
the medium. Substitution of an isoleucine or valine for
leucine at this position also signiﬁcantly reduced the rate
of processing and secretion of PCSK9 (ﬁg. 2B), which sug-
gests that leucine is required at this position and that the
adverse effect of the substitution of phenylalaninewas not
attributable simply to the introduction of a bulky aromatic
side chain. Thus, the L253F mutation interferes with au-
tocatalytic cleavage of PCSK9, which presumably reﬂects
decreased catalytic activity of the mutant protein.
PCSK9-679X Is Retained in the ER
In contrast to PCSK9-253F, recombinant PCSK9-679X un-
derwent rapid cleavage, but the mature protein accumu-
lated in the cells andwas not secreted (ﬁg. 2). To determine
the site of accumulation of the mature PCSK9-679X, we
examined the sensitivity of the N-linked sugar attached
to residue 533 to PNGaseF and endoglycosidaseH (EndoH)
(ﬁg. 3). In the cells expressing PCSK9-WT, the precursor
and mature forms of the protein remained sensitive to
both glycosidases. In contrast to these results, the secreted
form of the wild-type protein was resistant to EndoH, as
would be expected of a protein that had transitted through
the Golgi. This result is consistent with rapid secretion
of PCSK9 after autocatalytic cleavage. In cells expressing
PCSK9-679X, both the precursor and mature forms of
PCSK9 remained sensitive to EndoH, which indicates that
these forms of the protein reside in the ER (ﬁg. 3). Sub-
stitution of an alanine for asparagine at residue 533 did
not interfere with either the processing or the secretion
of PCSK9. These data suggest that the C679X mutation
spares catalytic activity but prevents normal folding of the
protein, which is thus retained in the ER.
C679X Is Retained in the ER Because of Aberrant Folding
The cysteine at residue 679 is the last of 18 cysteines in
the 269-aa C-terminal domain. The failure of PCSK9-679X
to transit out of the ER is presumably due to abnormal
disulﬁde bond formation, which results in improper pro-
tein folding. Aberrant folding of C679X was conﬁrmed by
inspection of the migration of the mutant protein on a
nonreducing gel after treatment with increasing concen-
trations of DTT (ﬁg. 4A). Substitution of either serine or
alanine for cysteine at residue 679 resulted in retention
of the mature protein in the ER. Introduction of cysteine
at position 680 or 681 failed to rescue trafﬁcking of the
protein (ﬁg. 4B). These results suggest a speciﬁc require-
ment for cysteine at residue 679. Introduction of a stop
mutation at residue 680 (but not at 681) also prevented
secretion of the protein. Thus, proper folding of the C-
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Figure 4. DTT reduction of PCSK9-679X and secretion of mutant
forms of PCSK9. A, Aliquots of the cell lysates and medium from
HEK-293 cells expressing wild-type (WT) or PCSK9-679X were
treated with increasing concentrations of DTT at RT for 1 h. Samples
were then subjected to 8% SDS-PAGE before immunoblotting. B,
The highly conserved cysteine C679 (top left) was mutated (top
right), and the constructs were expressed in HEK-293 cells (bot-
tom). Immunoblotting was performed on the cells and medium as
described in the ﬁgure 1 legend. Z. Fish p zebraﬁsh; P p pre-
cursor; M p mature; S p secreted.
Figure 5. Pedigree of a 32-year-old African American woman
(II.2) who is compound heterozygous for loss-of-function muta-
tions in PCSK9. A, The proband (I.2) of the family is a participant
in the Dallas Heart Study19 who was found to be heterozygous for
the Y142X allele in PCSK9. Fasting blood samples were obtained
from additional family members. Plasma and serum were isolated,
and the lipids and lipoprotein levels were measured using com-
mercial reagents (table 1). The LDL-C and age- and sex-adjusted
percentiles are provided for each family member. PCSK9 was im-
munoprecipitated from the plasma of selected family members with
use of a polyclonal anti-PCSK9 antibody (295A), was size-frac-
tionated by SDS-PAGE, and then was immunoblotted as described
in the “Material and Methods” section. Individual II.3 was sam-
pled, but the analysis of circulating PCSK9 was not performed on
this subject. B, PCSK9-WT (WT) and mutant PCSK9 (DR97) were
expressed in HEK-293 cells. After 2 d, the cell lysates and the
medium were collected and subjected to immunoblotting as de-
scribed in the ﬁgure 1 legend. NAp not available; Pp precursor;
M p mature; S p secreted.
terminal domain is not required for catalytic cleavage but
is required for secretion.
Identiﬁcation of a Compound Heterozygote with No
Circulating PCSK9
The three mutations in PCSK9 associated with the greatest
reductions in plasma levels of LDL-C prevent the secretion
of mature PCSK9 by disrupting the synthesis (Y142X),
cleavage (L253F), or folding (C679X) of the protein. On
the basis of these ﬁndings, we predicted that individuals
with these mutations would have reduced circulating lev-
els of PCSK9. To test this hypothesis, we examined the
relationship between the amount of circulating PCSK9 and
the segregation of the PCSK9 nonsense alleles in families.
In one such family, we identiﬁed an individual with no
immunodetectable circulating PCSK9 (ﬁg. 5A and table 1).
The proband of this family was a 53-year-old woman who
was a participant in the Dallas Heart Study.19 This subject
was heterozygous for the Y142X allele and had an LDL-C
level of 49 mg/dL (!1st percentile when compared with
age- and sex-matched controls). Genetic analysis of her
family revealed that her daughter and two of her grand-
daughters were also heterozygous for the nonsense mu-
tation. All four of the family members who were hetero-
zygous for the Y142X allele had LDL-C levels !1st percen-
tile when compared with age- and sex-matched controls.
However, the proband’s daughter (II.2) had a lower plasma
level of LDL-C (14 mg/dL) than that of either her mother
(49 mg/dL) and her children (30 mg/dL and 27 mg/dL);
since the daughter’s father was also hypocholesterolemic
(LDL-C of 39 mg/dL), we screened her PCSK9 gene for a
mutation on the paternal allele. DNA sequencing revealed
that II.2 was heterozygous for an in-frame 3-bp deletion
(c.290_292delGCC) that deletes an arginine at codon 97.
Expression of the mutant protein in HEK-293 cells re-
vealed that the mutation prevented autocatalytic cleavage
and secretion of PCSK9 (ﬁg. 5B).
Thus, II.2 is a compound heterozygote for mutations
that disrupt synthesis (maternal allele) and processing/
secretion (paternal allele) of PCSK9. If PCSK9 is secreted
from hepatocytes in vivo, II.2 would be predicted to have
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Table 1. Plasma Lipid and Lipoprotein Levels in Family Members of an Individual Who Is
a Compound Heterozygote for Loss-of-Function Mutations in PCSK9
Individual
Age
(years) Sex
Fasting Plasma Levels, in mg/dL (Percentile) PCSK9 Allelea
Cholesterol LDL-C HDL-Cb TGc 1 2
I.1 51 M 96 (!1st) 39 (!1st) 44 (55th) 88 (25th) DR97 WT
I.2 53 F 144 (!1st) 49 (!1st) 88 (90th) 51 (!1st) Y142X WT
II.1 10 F 137 (15th) 77 (20th) 49 (45th) 78 (50th) DR97 WT
II.2 32 F 96 (!1st) 14 (!1st) 65 (80th) 119 (70th) DR97 Y142X
II.3 28 F 152 (20th) 80 (15th) 59 (65th) 92 (55th) WT WT
III.1 6 M 106 (!1st) 30 (!1st) 65 (75th) 77 (75th) Y142X WT
III.2 3 F 106 (!1st) 37 (!1st) 59 (70th) 71 (55th) Y142X WT
III.3 13 F 174 (60th) 104 (60th) 55 (65th) 110 (75th) WT WT
NOTE.—Plasma lipid and lipoprotein levels were measured after a 12-h fast. The percentile of the lipid and
lipoprotein levels are compared with age- and sex-matched African American control individuals.
a WT p wild type.
b HDL-C p high-density lipoprotein cholesterol.
c TG p triglycerides.
no circulating PCSK9. To test this possibility, we examined
the plasma of each family member for the presence of
PCSK9. Immunoprecipitation of PCSK9 from 500 ml of
fasting plasma revealed a single band of the expected size
(64 kDa) in all family members except the proband’s
daughter (II.2).
Despite having no immunodetectable circulatingPCSK9
and an LDL-C of only 14 mg/dL, II.2 is an apparently
healthy, fertile, normotensive, college-educated woman
with normal liver and renal function tests (including uri-
nalysis) who works as an aerobics instructor.
Structural Model of PCSK9
To relate the functional characterization of the loss-of-
function variants to protein structure, we developed a
structural model of PCSK9 on the basis of homology with
fervidolysin, a keratin-degrading enzyme from the bacte-
rium Fervidobacterium pennivorans.23 Signiﬁcant sequence
similarity between PCSK9 and fervidolysin extends from
the subtilisin-like N-terminal prodomain (ﬁg. 6A [purple])
to the peptidase S8 catalytic domain (ﬁg. 6A [yellow]);
within these two domains, the two sequences can be
aligned with high conﬁdence (ﬁg. 6B). Additionally, both
proteins include a C-terminal extension from the catalytic
domain that is similar in length and secondary structure.
In fervidolysin, the C-terminus contains two b-sandwich
domain repeats that interact with both the prodomain
and the catalytic domain.23 In PCSK9, the C-terminus con-
tains a conserved cysteine-rich pattern (Cys # 6) repeated
three times within the context of predicted b-strands, sug-
gesting the presence of three—rather than two—C-termi-
nal domains. Thus, despite secondary structural similari-
ties between PCSK9 and fervidolysin, the topology of the
PCSK9 C-terminus remains ambiguous; accordingly, it is
represented as a space-ﬁlled model without a correspond-
ing alignment (ﬁg. 6).
In the PCSK9 model, the R46L substitution is located
within an N-terminal extension of the prodomain. In fer-
vidolysin, this N-terminal coil makes extensive contacts
with the C-terminal domain and is thought to contribute
to the association of the prodomain with the catalytic/C-
terminal domains, which is maintained after autocatalytic
cleavage.23 The substitution of a hydrophobic leucine for
a polar arginine within the corresponding region of PCSK9
may alter the association between the prodomain and the
catalytic domain/C-terminal domains after autocatalytic
cleavage. The arginine deleted at residue 97 in II.2 (family
DHS20) is predicted to disrupt an a-helix in the prodo-
main; the ﬁnding that this mutation prevents autocata-
lytic cleavage (ﬁg. 5B) is consistent with the prediction
that it would interfere with proper folding of the protein.
One of the gain-of-function mutations (S127R) is also lo-
cated in the prodomain and also reduces the rate of pro-
tein processing.11 The remaining two gain-of-functionmu-
tations (F216L and D374Y) are predicted to reside in close
proximity to each other on an external face of the catalytic
domain. Although the molecular consequences of these
mutations remain unknown, this mapping might point
to a role for these residues in interaction with another
protein. The loss-of-functionmutation L253F that impairs
processing (ﬁg. 2A) resides in close proximity to the cat-
alytic triad. The corresponding residue in fervidolysin
points toward the proteolytic cleavage site and is located
within 4 angstroms of the aspartate of the catalytic triad.
Leucine at this location in PCSK9 appears to be essential
and cannot be replaced by isoleucine, alanine, or phenyl-
alanine (ﬁg. 2B), which suggests that this residue helps po-
sition the PCSK9 peptide backbone for autocatalytic cleav-
age. Finally, the substitution of an alanine for a threonine
at amino acid 443 has only a modest effect on plasma
levels of LDL-C (homozygosity is associated with a 3.5%
reduction in plasma LDL-C level);5 it is not clear whether
the LDL-lowering effect of this substitution is a direct ef-
fect of the amino acid substitution or is due to a sequence
variation that is in linkage disequilibrium.5
Discussion
A major ﬁnding of this study is that PCSK9 circulates in
plasma and that those mutations associated with the
Figure 6. Structural model (A) and alignment of residues 31–450 of PCSK9 with fervidolysin (B). A, A model of PCSK9, generated
using coordinates from the crystal structure of fervidolysin (Protein Database ID 1r6v).23 The N-terminal prodomain (purple) is connected
to the catalytic domain (yellow) by a long, thickened coil. The prodomain cleavage site (color boundary) is near the catalytic triad
(red). PCSK9 mutations that map to the prodomain or catalytic domain are labeled and numbered according to the human sequence
and are depicted in blue (gain of function) or green (loss of function). Those mutations that reside in less accurately mapped regions
of the protein are represented by a range of residues (see the “Material and Methods” section). Three predicted C-terminal domains of
PCSK9 are represented as a space-ﬁll that is based on the two fervidolysin C-terminal domains. B, An alignment between PCSK9 and
the 1r6v N-terminal and catalytic domain sequences, generated with a fold-recognition program (Meta-BASIC). Compared with an
alignment made by BLAST (not shown), the residues whose positions in the alignment were in agreement with those obtained using
BLAST are in bold type, whereas those that differ are italicized. Noncapitalized residues in 1r6v represent positions where sequence
was deleted. Residues with predicted secondary structure are red (helix), blue (strand), and black (coil) and are compared with the
observed 1r6v secondary structure (cylinders and arrows shown above the alignment and colored as in panel A). Residues corresponding
to the catalytic triad, the gain-of-function mutations, and the loss-of-function mutations are highlighted with the colors and ranges
described for panel A.
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greatest reductions in plasma levels of LDL-C interfere
with either the synthesis or the secretion of PCSK9. These
observations led to the identiﬁcation of the ﬁrst known
compound heterozygote with two inactivating mutations
in PCSK9. Although PCSK9 is expressed in the brain, liver,
intestine, and kidneys,7 the compound heterozygote was
apparently healthy. Therefore, it appears that secretion of
PCSK9 is not essential for normal development and func-
tion. The normal fertility and development of the PCSK9-
knockout mice are consistent with this conclusion.13 We
cannot exclude the possibility that the mutant PCSK9 ex-
pressed from the DR97 allele, which remains sequestered
in the ER, serves some essential function; however, this
seems unlikely, since the mutation prevents autocatalytic
cleavage, which is required for the function of all other
proprotein convertases.25
Nonsense mutations in PCSK9 are relatively common
among individuals of African descent. In the United
States, 1 in every 40–50 African Americans has at least one
PCSK9 allele that contains a nonsense mutation.4,14 The
less frequent nonsense mutation (Y142X) occurs early in
the transcript in exon 3 and is located 51 nt upstream of
the exon-intron junction. These properties predict that
the mutant mRNA is recognized by the nonsense-medi-
ated mRNA-decay machinery. We failed to detect PCSK9
mRNA in leukocytes and were therefore unable to directly
conﬁrm that this mutation results in degradation of the
mRNA.5 To exclude the possibility that a peptide formed
from the Y142X allele might adversely affect the function
of the wild-type protein, we coexpressed the 14-kDa N-
terminal peptide and the wild-type protein in HEK-293
cells. The mutant peptide did not affect the synthesis,
cleavage, or secretion of the PCSK9-WT (data not shown).
Furthermore, Y142X heterozygotes have circulatingPCSK9,
presumably expressed from the normal allele, which sug-
gests that the nonsense allele does not prevent secretion
of the normal protein. These data are consistent with the
hypothesis that the Y142Xmutation acts as a loss-of-func-
tion mutation rather than as a gain-of-functionmutation.
The most common nonsense mutation of PCSK9 is pre-
dicted to truncate the protein by 14 aa (PCSK9-679X). This
mutation did not interfere with the synthesis or autocat-
alytic cleavage of PCSK9 but did prevent secretion of the
protein from cells (ﬁg. 2). These results are consistent with
the previous ﬁndings that recombinant PCSK9 containing
truncations at the C-terminal underwent normal autocat-
alytic cleavage.8,9 Analysis of the N-linked sugar attached
to residue 533 revealed that the mature, processed form
PCSK9-679X remained EndoH sensitive, which is consis-
tent with retention of the protein in the ER. Thus, a func-
tional catalytic domain is not sufﬁcient for the secretion
of PCSK9 or for its effect on modulating LDLR levels.
The PCSK9-679X mutation eliminates the ﬁnal cysteine
in the C-terminal domain. This cysteine has been highly
conserved through vertebrate evolution (ﬁg. 4B). When
either a serine or alanine was substituted for the cysteine,
the proteinwas retained in the ER. Introductionof another
cysteine downstream of the substituted cysteine failed to
rescue the trafﬁcking of the protein out of the ER, which
indicates that the presence and the spacing of the cysteine
residue in this region is critical for secretion. The aberrant
migration of the C679X mutant protein on SDS-PAGE af-
ter DTT reduction suggests that the absence of the last
cysteine residue interferes with proper disulﬁde formation
and protein folding. The failure of the processed protein
to transit out of the ER is consistent with PCSK9 acting
in a post-ER compartment, as suggested elsewhere.15
The very low level of plasma LDL-C in the compound
heterozygote reveals that circulating levels of LDL-C are
almost totally depleted in the absence of PCSK9. In con-
trast to other Mendelian forms of severe hypocholestero-
lemia—abetalipoproteinemia (MIM 200100) and homo-
zygous hypobetalipoproteinemia (MIM 107730), which
are both associated with malnutrition, steatorrhea, hepatic
steatosis, and manifestations of fat-soluble vitamin deﬁ-
ciency (night blindness and vibratory and proprioception
defects)26—hypocholesterolemia due todeﬁciencyofPCSK9
appears to be benign. Individuals heterozygous for a non-
sense mutation in PCSK9 do not have any detectable in-
crease in hepatic triglyceride content,5 which often ac-
companies heterozygous hypobetalipoproteinemia.27 The
differences in outcome between these conditions presum-
ably reﬂect the disparate mechanistic basis for the hypo-
cholesterolemia. Genetic defects in apolipoprotein B or
microsomal triglyceride transfer protein (MIM 157147)
prevent formation of chylomicrons, thus limiting the ab-
sorption of fat-soluble vitamins and the secretion of the
LDL precursor lipoprotein, very-low-density lipoprotein.26
Although it remains controversial,28,29 the hypocholestero-
lemia associated with PCSK9 deﬁciency appears to be
caused primarily by increased LDL clearance and not by
reduced lipoprotein production.12,13,30
The observation that PCSK9 deﬁciency is associated with
very low LDL-C levels in an otherwise healthy individual
makes PCSK9 an attractive therapeutic target. We have
shown elsewhere that heterozygotes for loss-of-function
mutations in PCSK9 enjoy signiﬁcant protection from cor-
onary heart disease.14 Taken together with the results of
the present study, these ﬁndings are consistent with the
notion that inhibition of PCSK9 should be a safe and ef-
fective strategy for the primary prevention of coronary
heart disease.
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